HOOKIPA Pharma (HOOK) announced the appointment of Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024. Dr. Winderlich has rich experience leading multiple candidates through the drug development process to product approval in the United States and in Europe. Dr. Winderlich joins HOOKIPA from Evotec SE (EVO), where he has served as Executive Vice President, Head of Global Scientific Operations. Dr. Malte Peters will continue to serve as ad interim Senior Clinical Advisor until the effective date. At such time, Dr. Peters will remain on the Company’s board of directors as an independent director.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOOK:
- HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
- Hookipa Pharma files to sell 15M shares of common stock for holders
- HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
- Hookipa Pharma announces $21.25M equity investment from Gilead
- Biotech Alert: Searches spiking for these stocks today
